A Randomized, Double-Blind, Active-Controlled Study of Patients With Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled With Simvastatin or Atorvastatin: Comparison of Switching to Combination Tablet Ezetimibe/Simvastatin vs Switching to Rosuvastatin or Doubling the Statin Dose.

Trial Profile

A Randomized, Double-Blind, Active-Controlled Study of Patients With Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled With Simvastatin or Atorvastatin: Comparison of Switching to Combination Tablet Ezetimibe/Simvastatin vs Switching to Rosuvastatin or Doubling the Statin Dose.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Ezetimibe/simvastatin (Primary) ; Atorvastatin; Rosuvastatin; Simvastatin
  • Indications Cardiovascular disorders; Hyperlipidaemia
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Nov 2011 Results presented at the 84th Annual Scientific Sessions of the American Heart Association.
    • 25 Mar 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top